首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core
Authors:Shen Dong-Ming  Brady Edward J  Candelore Mari R  Dallas-Yang Qing  Ding Victor D-H  Feeney William P  Jiang Guoquiang  McCann Margaret E  Mock Steve  Qureshi Sajjad A  Saperstein Richard  Shen Xiaolan  Tong Xinchun  Tota Laurie M  Wright Michael J  Yang Xiaodong  Zheng Song  Chapman Kevin T  Zhang Bei B  Tata James R  Parmee Emma R
Institution:a Department of Basic Chemistry, Merck Research Laboratories, PO Box 2000, RY50G-346, Rahway, NJ 07065, USA
b Department of Pharmacology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
c Department of Metabolic Disorders and Molecular Endocrinology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
d Laboratory Animal Resourcesd, Merck Research Laboratories, PO Box 2000, RY50G-346 Rahway, NJ 07065, USA
Abstract:A novel class of 1,3,5-pyrazoles has been discovered as potent human glucagon receptor antagonists. Notably, compound 26 is orally bioavailable in several preclinical species and shows selectivity towards cardiac ion channels, other family B receptors such hGIP and hGLP1, and a large panel of enzymes and additional receptors. When dosed orally, compound 26 is efficacious in suppressing glucagon induced plasma glucose excursion in rhesus monkey and transgenic murine pharmacodynamic models at 1 and 10 mpk, respectively.
Keywords:Glucagon receptor antagonists  Pyrazole  Diabetes
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号